Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6623919 | 0.93 | ADORA2A (0.58) | ADORA2AADORA1 | |
| SCHEMBL6625218 | 0.91 | ADORA2A (0.57) | ADORA2AADORA1 | |
| SCHEMBL6625998 | 0.90 | ADORA2A (0.60) | ADORA2AADORA1 | |
| SCHEMBL6626854 | 0.90 | ADORA2A (0.60) | ADORA2AADORA1 | |
| SCHEMBL5545893 | 0.88 | ADORA2A (0.59) | ADORA2AADORA1 | |
| SCHEMBL6625949 | 0.88 | ADORA2A (0.58) | ADORA2AADORA1 | |
| SCHEMBL6626072 | 0.88 | ADORA2A (0.58) | ADORA2AADORA1 | |
| SCHEMBL6629912 | 0.88 | ADORA2A (0.62) | ADORA2AADORA1 | |
| SCHEMBL2927933 | 0.88 | ADORA2A (0.56) | ADORA2AADORA1 | |
| SCHEMBL6625297 | 0.87 | ADORA2A (0.58) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2564871-B1 | Therapeutic Agent for Migraine | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-9254283-B2 | Therapeutic agent for migraine | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-20110183992-A1 | THERAPEUTIC AGENT FOR MIGRAINE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| US-20110183992-A1 | THERAPEUTIC AGENT FOR MIGRAINE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| EP-0976753-B1 | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6222035-B1 | AS ADENOSINE A.SUB.2A RECEPTOR ANTAGONISTS AND ARE USEFUL FOR THERAPY OR OR PROPHYLAXIS OF VARIOUS DISEASES INDUCED BY HYPERACTIVITY OF ADENOSINE A.SUB.2A RECEPTORS SUCH AS PARKINSON'S DISEASE, SENILE DEMENTIA OR DEPRESSION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0976753-A1 | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183992-A1 | THERAPEUTIC AGENT FOR MIGRAINE | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.